Achieving Treatment Goals for Hormone-Refractory Prostate Cancer With Chemotherapy

Achieving Treatment Goals for Hormone-Refractory Prostate Cancer With Chemotherapy William Berry, Mario Eisenberger Oncologist 2005; 10: 30-39 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in genitourinary cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the efficacy and toxicity results of two phase III trials that evaluated a docetaxel-based regimen for the treatment of HRPC. Identify end points that are being evaluated as surrogates to survival in HRPC trials. List agents under investigation for the second-line treatment of HRPC. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Dec. 19, 2005 Most Recent Review: Dec. 19, 2005* Most Recent Update: Dec. 19, 2005 Date Credit Expires: Dec. 19, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.